ENTX241220P2500
- 0.00
- 0.000.00%
Entera Bio Newsroom
Express News | HC Wainwright & Co. Reiterates Buy on Entera Bio, Maintains $10 Price Target
Entera Bio Buy Rating: Strong Financials, Strategic Developments, and Promising Pipeline Drive Analyst Confidence
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
10-Q: Q3 2024 Earnings Report
Express News | Entera Bio Q3 2024 GAAP EPS $(0.08) Misses $(0.06) Estimate, Sales $42.00K Beat $40.00K Estimate
Entera Bio 3Q Rev $42,000 >ENTX
Entera Bio 3Q Loss/Shr 8c >ENTX
Earnings Flash (ENTX) ENTERA BIO Reports Q3 Revenue $42,000
Express News | Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
Press Release: Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
Entera Bio Analyst Ratings
Buy Rating Affirmed for Entera Bio's EB613: A Game Changer in Osteoporosis Treatment
Analysts Are Bullish on These Healthcare Stocks: Entera Bio (ENTX), Legend Biotech (LEGN)
Entera Bio Shares Are Trading Higher After the Company Announced Results Showing Significant Systemic Exposure and a Favorable PK Profile in Its Obesity and Metabolic Disorder Studies.
Express News | Entera Bio Shares Are Trading Higher After the Company Announced Results Showing Significant Systemic Exposure and a Favorable PK Profile in Its Obesity and Metabolic Disorder Studies
Express News | Entera Bio Ltd - Oral Oxm Reduced Plasma Glucose Levels Significantly
Express News | Entera Bio and OPKO Health Provide Update on Pk/Pd Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Entera Bio to Participate in Upcoming Investor and Scientific Conferences